News
AVDL
18.18
-2.36%
-0.44
Avadel Pharmaceuticals plc Q1 2024 Earnings Preview
Avadel Pharmaceuticals plc (NASDAQ:AVDL) is scheduled to announce Q1 earnings results on Wednesday, May 8th. The company is expected to report earnings of -$0.01 per share. The consensus revenue estimate is $25.9 million.
Seeking Alpha · 12h ago
Notable earnings before Wednesday's open
Major earnings expected before the bell on Wednesday include: Brookfield Asset Management (BAM) Emerson Electric (EMR) Shopify (SHOP) Teva Pharmaceutical Industries (TEVA) Uber Technologies (UBER) Other earnings slated for release before Wednesday's open.
Seeking Alpha · 12h ago
Weekly Report: what happened at AVDL last week (0429-0503)?
Weekly Report · 1d ago
Weekly Report: what happened at AVDL last week (0422-0426)?
Weekly Report · 04/29 10:16
Avadel Pharmaceu: [Amend]Annual Report
Press release · 04/27 07:40
Weekly Report: what happened at AVDL last week (0415-0419)?
Weekly Report · 04/22 10:11
Jazz Pharmaceuticals: Cheap But Complicated
Seeking Alpha · 04/18 17:26
Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
TipRanks · 04/15 11:12
AVADEL PHARMACEUTICALS PLC: EFFECTIVE APRIL 15, CO'S ORDINARY SHARES LISTED DIRECTLY ON NASDAQ STOCK MARKET
Reuters · 04/15 11:04
AVADEL PHARMACEUTICALS PLC: CAUSED MANDATORY EXCHANGE OF ADSS FOR UNDERLYING ORDINARY SHARES
Reuters · 04/15 11:04
Weekly Report: what happened at AVDL last week (0408-0412)?
Weekly Report · 04/15 10:06
Weekly Report: what happened at AVDL last week (0401-0405)?
Weekly Report · 04/08 10:09
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Avadel Pharmaceuticals reports strong Q4 2023 earnings for lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in the treatment of the condition. The company's sales ramp expectation for 2024 is optimistic. We maintain a buy rating on the company.
Seeking Alpha · 04/02 07:40
Weekly Report: what happened at AVDL last week (0325-0329)?
Weekly Report · 04/01 10:08
Weekly Report: what happened at AVDL last week (0318-0322)?
Weekly Report · 03/25 10:10
Weekly Report: what happened at AVDL last week (0311-0315)?
Weekly Report · 03/18 10:09
Weekly Report: what happened at AVDL last week (0304-0308)?
Weekly Report · 03/11 10:07
Buy Rating Affirmed for Avadel Pharmaceuticals Amid Strong Q4 Performance and Promising Growth Prospects
TipRanks · 03/07 04:15
Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Avadel Pharmaceuticals plc's stock is up 51% since my "Buy" recommendation in November. Avadel's Lumryz's market penetration and unique once-nightly dosing advantage are driving optimistic revenue forecasts and operational breakeven projections. A jury awarded Avadel a 3.5% royalty rate on Jazz Pharmaceuticals' Xyrem patent. The company's stock rose 18% after Q4 earnings.
Seeking Alpha · 03/05 19:00
Avadel Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Dow Jones · 03/05 14:32
More
Webull provides a variety of real-time AVDL stock news. You can receive the latest news about Avadel Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.